Cone-Rod Dystrophy Market 2018 Dynamics – Drivers, Restrains, Opportunities, Challenges and Forecasts to 2023

“Cone-Rod Dystrophy Market”
The Global Cone-Rod Dystrophy Market has been segmented on the basis of types, diagnosis, treatment, and end user. On the basis of the diagnosis, the market is segmented into Electroretinogram (ERG), clinical history, fundus examination, molecular diagnosis, and others.

The World Cone-Rod Dystrophy Market Highlights:

Cone-Rod Dystrophy is a group of related eye disorders that cause gradual loss of vision due to retinal deterioration this may lead to increasing severity or even blindness. Generally, the disorders affects the rod and cones cells present in the retina which are responsible for vision and clarity. According to NCBI, prevalence of cone-rod dystrophies is estimated to be 1 in every 40,000 cases.

According to World Health Organization, in 2014, worldwide 285 million people were estimated to be visually impaired, out of which nearly 246 million have low vision and 39 million are completely blind. Uncorrected errors are the major reasons for causing moderate and severe visual impairment. But still, 80% of the ophthalmic diseases can be cured or prevented by treatment.

There are many new low vision aids, including telescopic and magnifying lenses, providing plenty of choice for users at all stages of sight loss. This technology has also removed many barriers to education and employment. According to American Academy of Ophthalmology, more than 25% of America’s population suffer from minor or major visual complication. More than 150 million Americans use corrective eyewear and spend more than $15 billion each year on eyewear.

Get Exclusive Sample Copy @ .

Ophthalmic impairment is caused due to a number of diseases like infectious diseases, genetic factor and many more, but diabetes have a major impact on the growth of the market. Diabetes is one of the important disorder responsible for causing visual impairment as it damages retinal blood vessels. According to WHO, 422 million people are suffering from diabetes and this number is increasing at the rate of 8.5%. According to the American Academy of Ophthalmology, diabetes is responsible for causing visual complication in approximately 4.5 million Americans.

This disorder can be curbed to a great extent by proper use of vitamin supplements therefore the cone rod dystrophy market is majorly effected by the Thiamine supplements. The growth of the vitamin industry is due to the increased per-capita income and increased health awareness among people. As the people are getting more aware about taking care of their health, they are giving more importance to these supplements to prevent various deficiencies. Online retailing of these supplements has further increased accessibility and has increased the customer base and it has also increased the convenience of buying which will indirectly effect the Cone Rod Dystrophy market.

Despite the lack of current treatments for cone-rod dystrophies, general eye check-ups are important. Furthermore, the people suffering from this conditions may experience other kinds of eye problems. Patients with cone rod dystrophy tend to develop cataracts at an earlier age as compared to the unaffected population.

Currently, there is no treatment to stop a person with Cone Rod Dystrophy (CRD) from losing their vision. Possible future treatments for CRD may include gene therapy, stem cell therapy, and retinal implants. The beta-carotenoids, lutein and zeaxanthin, have been evidenced to reduce the risk of developing to Cone dystrophy sufferers.

The Global Cone-Rod Dystrophy Market is expected to grow at a CAGR of approximately 5.3% during the forecast period 2017-2023.

Cone-Rod Dystrophy Market Key Players:

Some of key the players in the global cone-rod dystrophy market are GlaxoSmithKline Plc. (U.S.), Johnson & Johnson (U.S.), Sanofi (Switzerland), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Abbott Laboratories (U.S.), Sunovion Pharmaceuticals (U.S.), Cephalon (U.S.), DSM (India), Amway (U.S.), Vitamin Shoppe (U.S.), Intas Pharmaceutials Limited (India), Sun Pharmaceuticals Ltd. (India) Emcure Pharmaceuticals Limited (India), Nutrilite (U.S.), NutraScience Labs (U.S.), and others.

Order a Premium Copy of 90 Pages Report Enabled with Respective Tables and Figures is Available @ .

Major T.O.C Cone-Rod Dystrophy Market:

  1. Report Prologue
  2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

  1. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

  1. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

T.O.C Continued……

Ask Questions to Expertise @ .



Table 1 Cone rod dystrophy Industry Synopsis, 2017 – 2023

Table 2 Cone rod dystrophy Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Cone rod dystrophy Market by Region, 2017 – 2023, (USD Million)

Table 4 Cone rod dystrophy Market by Diagnosis, 2017 – 2023, (USD Million)

Table 5 Cone rod dystrophy Market by Treatment, 2017 – 2023, (USD Million)

Table 6 Cone rod dystrophy Market by End Users, 2017 – 2023, (USD Million)

Table 7 North America Cone rod dystrophy Market by Diagnosis, 2017 – 2023, (USD Million)


Figure 1 Research Process

Figure 2 Segmentation for Cone rod dystrophy Market

Figure 3 Segmentation Market Dynamics for Cone rod dystrophy Market

Figure 4 Global Cone rod dystrophy Market Share, by Diagnosis 2016

Figure 5 Global Cone rod dystrophy Market Share, by Treatment 2016

Figure 6 Global Cone rod dystrophy Market Share, by End Users, 2016

Figure 7 Global Cone rod dystrophy Market Share, by Region, 2016

& More

Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India